Huadong Medicine: Icariin Soft Capsule is a 1.2-type innovative drug of traditional Chinese medicine approved in January 2022, and it is less likely to be included in the national centralized procurement. Post date May 17, 2022 — 16:00 Post Lock Read More Technology growth style broke out, Shuangchuang 50ETF (159781) rose 1.35%-Funds-Financial Industry Post date May 17, 2022 — 14:55 Post Lock Read More Hepatitis concept, new crown treatment, traditional Chinese medicine and other pharmaceutical stocks fell Post date May 17, 2022 — 10:27 Post Lock Read More "New crown drug" Qianjintiansu drives the stock price limit of many traditional Chinese medicine companies. The inventor responded: it has nothing to do with us-Stock Channel-Hexun Network Post date May 17, 2022 — 09:49 Post Lock Read More Zhongheng Group: The company's pharmaceutical research and development direction is mainly concentrated in the field of traditional Chinese medicine research and development, mainly in the fields of cardiovascular and cerebrovascular, classic traditional Chinese medicine and other fields Post date May 17, 2022 — 09:30 Post Lock Read More Zhongheng Group: The company has no direct research investment in Chinese patent medicine for new coronary pneumonia for the time being Post date May 17, 2022 — 09:21 Post Lock Read More Qianjin Pharmaceutical does not have Qianjin Tensudo to clarify the connection! Note that the inhibition data of 15,000 times the risk is only the result of in vitro experiments Post date May 16, 2022 — 23:09 Post Lock Read More Qianjin Pharmaceutical has no Qianjin phylloxacin, and many companies clarify the relationship! Pay attention to the risks, the inhibition data of 15,000 times are only the results of in vitro experiments. Post date May 16, 2022 — 23:07 Post Lock Read More Yunnan Baiyao: The company currently does not produce and sell fenugreek related products Post date May 16, 2022 — 23:00 Post Lock Read More It's not just you who have been cut leeks by the stock market! Yunnan Baiyao’s net profit fell 49% last year, and it lost nearly 2 billion by indulging in stocks Post date May 16, 2022 — 14:38 Post Lock Read More Zhendong Pharmaceutical: Filling the blank of Chinese medicine industry standards and realizing the rapid development of Chinese medicine industry Post date May 16, 2022 — 13:32 Post Lock Read More Zhendong Pharma helps the front line of Shanghai's anti-epidemic efforts and works together to keep "Shanghai" Post date May 16, 2022 — 13:14 Post Lock Read More Huaan Securities: Buy rating for Shouxiangu Post date May 16, 2022 — 10:12 Post Lock Read More [Opportunity Discovery] The Health and Health Commission requires the routine construction or renovation of a certain number of makeshift hospitals related companies or attracts attention_Oriental Fortune Net Post date May 16, 2022 — 09:00 Post Lock Read More Heavy analysis! Where did the core assets fall? Nearly half of the constituent stocks of the Mao Index fell by more than 50%, and many indexes retreated more than 2018. Some stocks have become the pioneers of rebound Post date May 16, 2022 — 08:55 Post Lock Read More [Opportunity Discovery] The Health and Health Commission requires companies related to the routine construction or renovation of a certain number of makeshift hospitals or has attracted attention Post date May 16, 2022 — 08:55 Post Lock Read More Zhongsheng Ruichuang's 3CL protease inhibitor clinical trial application was accepted by NMPA, and domestic new crown drugs accelerated Post date May 16, 2022 — 08:44 Post Lock Read More Ping An Securities: Give Xintian Pharmaceutical an Overweight Rating_Stock News_Market Gold Online Post date May 16, 2022 — 08:37 Post Lock Read More New crown oral drug clinical trial approved! Chinese medicine doubled the application of bull stocks after four days, and then made good profits, and institutions fled at high levels – yqqlm Post date May 15, 2022 — 23:27 Post Lock Read More *ST Kangmei appoints Liu Xinquan as the company's deputy general manager. The company's net profit in 2021 is 7.918 billion. Post date May 15, 2022 — 22:23 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Technology growth style broke out, Shuangchuang 50ETF (159781) rose 1.35%-Funds-Financial Industry Post date May 17, 2022 — 14:55 Post Lock Read More Hepatitis concept, new crown treatment, traditional Chinese medicine and other pharmaceutical stocks fell Post date May 17, 2022 — 10:27 Post Lock Read More "New crown drug" Qianjintiansu drives the stock price limit of many traditional Chinese medicine companies. The inventor responded: it has nothing to do with us-Stock Channel-Hexun Network Post date May 17, 2022 — 09:49 Post Lock Read More Zhongheng Group: The company's pharmaceutical research and development direction is mainly concentrated in the field of traditional Chinese medicine research and development, mainly in the fields of cardiovascular and cerebrovascular, classic traditional Chinese medicine and other fields Post date May 17, 2022 — 09:30 Post Lock Read More Zhongheng Group: The company has no direct research investment in Chinese patent medicine for new coronary pneumonia for the time being Post date May 17, 2022 — 09:21 Post Lock Read More Qianjin Pharmaceutical does not have Qianjin Tensudo to clarify the connection! Note that the inhibition data of 15,000 times the risk is only the result of in vitro experiments Post date May 16, 2022 — 23:09 Post Lock Read More Qianjin Pharmaceutical has no Qianjin phylloxacin, and many companies clarify the relationship! Pay attention to the risks, the inhibition data of 15,000 times are only the results of in vitro experiments. Post date May 16, 2022 — 23:07 Post Lock Read More Yunnan Baiyao: The company currently does not produce and sell fenugreek related products Post date May 16, 2022 — 23:00 Post Lock Read More It's not just you who have been cut leeks by the stock market! Yunnan Baiyao’s net profit fell 49% last year, and it lost nearly 2 billion by indulging in stocks Post date May 16, 2022 — 14:38 Post Lock Read More Zhendong Pharmaceutical: Filling the blank of Chinese medicine industry standards and realizing the rapid development of Chinese medicine industry Post date May 16, 2022 — 13:32 Post Lock Read More Zhendong Pharma helps the front line of Shanghai's anti-epidemic efforts and works together to keep "Shanghai" Post date May 16, 2022 — 13:14 Post Lock Read More Huaan Securities: Buy rating for Shouxiangu Post date May 16, 2022 — 10:12 Post Lock Read More [Opportunity Discovery] The Health and Health Commission requires the routine construction or renovation of a certain number of makeshift hospitals related companies or attracts attention_Oriental Fortune Net Post date May 16, 2022 — 09:00 Post Lock Read More Heavy analysis! Where did the core assets fall? Nearly half of the constituent stocks of the Mao Index fell by more than 50%, and many indexes retreated more than 2018. Some stocks have become the pioneers of rebound Post date May 16, 2022 — 08:55 Post Lock Read More [Opportunity Discovery] The Health and Health Commission requires companies related to the routine construction or renovation of a certain number of makeshift hospitals or has attracted attention Post date May 16, 2022 — 08:55 Post Lock Read More Zhongsheng Ruichuang's 3CL protease inhibitor clinical trial application was accepted by NMPA, and domestic new crown drugs accelerated Post date May 16, 2022 — 08:44 Post Lock Read More Ping An Securities: Give Xintian Pharmaceutical an Overweight Rating_Stock News_Market Gold Online Post date May 16, 2022 — 08:37 Post Lock Read More New crown oral drug clinical trial approved! Chinese medicine doubled the application of bull stocks after four days, and then made good profits, and institutions fled at high levels – yqqlm Post date May 15, 2022 — 23:27 Post Lock Read More *ST Kangmei appoints Liu Xinquan as the company's deputy general manager. The company's net profit in 2021 is 7.918 billion. Post date May 15, 2022 — 22:23 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Hepatitis concept, new crown treatment, traditional Chinese medicine and other pharmaceutical stocks fell Post date May 17, 2022 — 10:27 Post Lock Read More "New crown drug" Qianjintiansu drives the stock price limit of many traditional Chinese medicine companies. The inventor responded: it has nothing to do with us-Stock Channel-Hexun Network Post date May 17, 2022 — 09:49 Post Lock Read More Zhongheng Group: The company's pharmaceutical research and development direction is mainly concentrated in the field of traditional Chinese medicine research and development, mainly in the fields of cardiovascular and cerebrovascular, classic traditional Chinese medicine and other fields Post date May 17, 2022 — 09:30 Post Lock Read More Zhongheng Group: The company has no direct research investment in Chinese patent medicine for new coronary pneumonia for the time being Post date May 17, 2022 — 09:21 Post Lock Read More Qianjin Pharmaceutical does not have Qianjin Tensudo to clarify the connection! Note that the inhibition data of 15,000 times the risk is only the result of in vitro experiments Post date May 16, 2022 — 23:09 Post Lock Read More Qianjin Pharmaceutical has no Qianjin phylloxacin, and many companies clarify the relationship! Pay attention to the risks, the inhibition data of 15,000 times are only the results of in vitro experiments. Post date May 16, 2022 — 23:07 Post Lock Read More Yunnan Baiyao: The company currently does not produce and sell fenugreek related products Post date May 16, 2022 — 23:00 Post Lock Read More It's not just you who have been cut leeks by the stock market! Yunnan Baiyao’s net profit fell 49% last year, and it lost nearly 2 billion by indulging in stocks Post date May 16, 2022 — 14:38 Post Lock Read More Zhendong Pharmaceutical: Filling the blank of Chinese medicine industry standards and realizing the rapid development of Chinese medicine industry Post date May 16, 2022 — 13:32 Post Lock Read More Zhendong Pharma helps the front line of Shanghai's anti-epidemic efforts and works together to keep "Shanghai" Post date May 16, 2022 — 13:14 Post Lock Read More Huaan Securities: Buy rating for Shouxiangu Post date May 16, 2022 — 10:12 Post Lock Read More [Opportunity Discovery] The Health and Health Commission requires the routine construction or renovation of a certain number of makeshift hospitals related companies or attracts attention_Oriental Fortune Net Post date May 16, 2022 — 09:00 Post Lock Read More Heavy analysis! Where did the core assets fall? Nearly half of the constituent stocks of the Mao Index fell by more than 50%, and many indexes retreated more than 2018. Some stocks have become the pioneers of rebound Post date May 16, 2022 — 08:55 Post Lock Read More [Opportunity Discovery] The Health and Health Commission requires companies related to the routine construction or renovation of a certain number of makeshift hospitals or has attracted attention Post date May 16, 2022 — 08:55 Post Lock Read More Zhongsheng Ruichuang's 3CL protease inhibitor clinical trial application was accepted by NMPA, and domestic new crown drugs accelerated Post date May 16, 2022 — 08:44 Post Lock Read More Ping An Securities: Give Xintian Pharmaceutical an Overweight Rating_Stock News_Market Gold Online Post date May 16, 2022 — 08:37 Post Lock Read More New crown oral drug clinical trial approved! Chinese medicine doubled the application of bull stocks after four days, and then made good profits, and institutions fled at high levels – yqqlm Post date May 15, 2022 — 23:27 Post Lock Read More *ST Kangmei appoints Liu Xinquan as the company's deputy general manager. The company's net profit in 2021 is 7.918 billion. Post date May 15, 2022 — 22:23 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
"New crown drug" Qianjintiansu drives the stock price limit of many traditional Chinese medicine companies. The inventor responded: it has nothing to do with us-Stock Channel-Hexun Network Post date May 17, 2022 — 09:49 Post Lock Read More Zhongheng Group: The company's pharmaceutical research and development direction is mainly concentrated in the field of traditional Chinese medicine research and development, mainly in the fields of cardiovascular and cerebrovascular, classic traditional Chinese medicine and other fields Post date May 17, 2022 — 09:30 Post Lock Read More Zhongheng Group: The company has no direct research investment in Chinese patent medicine for new coronary pneumonia for the time being Post date May 17, 2022 — 09:21 Post Lock Read More Qianjin Pharmaceutical does not have Qianjin Tensudo to clarify the connection! Note that the inhibition data of 15,000 times the risk is only the result of in vitro experiments Post date May 16, 2022 — 23:09 Post Lock Read More Qianjin Pharmaceutical has no Qianjin phylloxacin, and many companies clarify the relationship! Pay attention to the risks, the inhibition data of 15,000 times are only the results of in vitro experiments. Post date May 16, 2022 — 23:07 Post Lock Read More Yunnan Baiyao: The company currently does not produce and sell fenugreek related products Post date May 16, 2022 — 23:00 Post Lock Read More It's not just you who have been cut leeks by the stock market! Yunnan Baiyao’s net profit fell 49% last year, and it lost nearly 2 billion by indulging in stocks Post date May 16, 2022 — 14:38 Post Lock Read More Zhendong Pharmaceutical: Filling the blank of Chinese medicine industry standards and realizing the rapid development of Chinese medicine industry Post date May 16, 2022 — 13:32 Post Lock Read More Zhendong Pharma helps the front line of Shanghai's anti-epidemic efforts and works together to keep "Shanghai" Post date May 16, 2022 — 13:14 Post Lock Read More Huaan Securities: Buy rating for Shouxiangu Post date May 16, 2022 — 10:12 Post Lock Read More [Opportunity Discovery] The Health and Health Commission requires the routine construction or renovation of a certain number of makeshift hospitals related companies or attracts attention_Oriental Fortune Net Post date May 16, 2022 — 09:00 Post Lock Read More Heavy analysis! Where did the core assets fall? Nearly half of the constituent stocks of the Mao Index fell by more than 50%, and many indexes retreated more than 2018. Some stocks have become the pioneers of rebound Post date May 16, 2022 — 08:55 Post Lock Read More [Opportunity Discovery] The Health and Health Commission requires companies related to the routine construction or renovation of a certain number of makeshift hospitals or has attracted attention Post date May 16, 2022 — 08:55 Post Lock Read More Zhongsheng Ruichuang's 3CL protease inhibitor clinical trial application was accepted by NMPA, and domestic new crown drugs accelerated Post date May 16, 2022 — 08:44 Post Lock Read More Ping An Securities: Give Xintian Pharmaceutical an Overweight Rating_Stock News_Market Gold Online Post date May 16, 2022 — 08:37 Post Lock Read More New crown oral drug clinical trial approved! Chinese medicine doubled the application of bull stocks after four days, and then made good profits, and institutions fled at high levels – yqqlm Post date May 15, 2022 — 23:27 Post Lock Read More *ST Kangmei appoints Liu Xinquan as the company's deputy general manager. The company's net profit in 2021 is 7.918 billion. Post date May 15, 2022 — 22:23 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Zhongheng Group: The company's pharmaceutical research and development direction is mainly concentrated in the field of traditional Chinese medicine research and development, mainly in the fields of cardiovascular and cerebrovascular, classic traditional Chinese medicine and other fields Post date May 17, 2022 — 09:30 Post Lock Read More Zhongheng Group: The company has no direct research investment in Chinese patent medicine for new coronary pneumonia for the time being Post date May 17, 2022 — 09:21 Post Lock Read More Qianjin Pharmaceutical does not have Qianjin Tensudo to clarify the connection! Note that the inhibition data of 15,000 times the risk is only the result of in vitro experiments Post date May 16, 2022 — 23:09 Post Lock Read More Qianjin Pharmaceutical has no Qianjin phylloxacin, and many companies clarify the relationship! Pay attention to the risks, the inhibition data of 15,000 times are only the results of in vitro experiments. Post date May 16, 2022 — 23:07 Post Lock Read More Yunnan Baiyao: The company currently does not produce and sell fenugreek related products Post date May 16, 2022 — 23:00 Post Lock Read More It's not just you who have been cut leeks by the stock market! Yunnan Baiyao’s net profit fell 49% last year, and it lost nearly 2 billion by indulging in stocks Post date May 16, 2022 — 14:38 Post Lock Read More Zhendong Pharmaceutical: Filling the blank of Chinese medicine industry standards and realizing the rapid development of Chinese medicine industry Post date May 16, 2022 — 13:32 Post Lock Read More Zhendong Pharma helps the front line of Shanghai's anti-epidemic efforts and works together to keep "Shanghai" Post date May 16, 2022 — 13:14 Post Lock Read More Huaan Securities: Buy rating for Shouxiangu Post date May 16, 2022 — 10:12 Post Lock Read More [Opportunity Discovery] The Health and Health Commission requires the routine construction or renovation of a certain number of makeshift hospitals related companies or attracts attention_Oriental Fortune Net Post date May 16, 2022 — 09:00 Post Lock Read More Heavy analysis! Where did the core assets fall? Nearly half of the constituent stocks of the Mao Index fell by more than 50%, and many indexes retreated more than 2018. Some stocks have become the pioneers of rebound Post date May 16, 2022 — 08:55 Post Lock Read More [Opportunity Discovery] The Health and Health Commission requires companies related to the routine construction or renovation of a certain number of makeshift hospitals or has attracted attention Post date May 16, 2022 — 08:55 Post Lock Read More Zhongsheng Ruichuang's 3CL protease inhibitor clinical trial application was accepted by NMPA, and domestic new crown drugs accelerated Post date May 16, 2022 — 08:44 Post Lock Read More Ping An Securities: Give Xintian Pharmaceutical an Overweight Rating_Stock News_Market Gold Online Post date May 16, 2022 — 08:37 Post Lock Read More New crown oral drug clinical trial approved! Chinese medicine doubled the application of bull stocks after four days, and then made good profits, and institutions fled at high levels – yqqlm Post date May 15, 2022 — 23:27 Post Lock Read More *ST Kangmei appoints Liu Xinquan as the company's deputy general manager. The company's net profit in 2021 is 7.918 billion. Post date May 15, 2022 — 22:23 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Zhongheng Group: The company has no direct research investment in Chinese patent medicine for new coronary pneumonia for the time being Post date May 17, 2022 — 09:21 Post Lock Read More Qianjin Pharmaceutical does not have Qianjin Tensudo to clarify the connection! Note that the inhibition data of 15,000 times the risk is only the result of in vitro experiments Post date May 16, 2022 — 23:09 Post Lock Read More Qianjin Pharmaceutical has no Qianjin phylloxacin, and many companies clarify the relationship! Pay attention to the risks, the inhibition data of 15,000 times are only the results of in vitro experiments. Post date May 16, 2022 — 23:07 Post Lock Read More Yunnan Baiyao: The company currently does not produce and sell fenugreek related products Post date May 16, 2022 — 23:00 Post Lock Read More It's not just you who have been cut leeks by the stock market! Yunnan Baiyao’s net profit fell 49% last year, and it lost nearly 2 billion by indulging in stocks Post date May 16, 2022 — 14:38 Post Lock Read More Zhendong Pharmaceutical: Filling the blank of Chinese medicine industry standards and realizing the rapid development of Chinese medicine industry Post date May 16, 2022 — 13:32 Post Lock Read More Zhendong Pharma helps the front line of Shanghai's anti-epidemic efforts and works together to keep "Shanghai" Post date May 16, 2022 — 13:14 Post Lock Read More Huaan Securities: Buy rating for Shouxiangu Post date May 16, 2022 — 10:12 Post Lock Read More [Opportunity Discovery] The Health and Health Commission requires the routine construction or renovation of a certain number of makeshift hospitals related companies or attracts attention_Oriental Fortune Net Post date May 16, 2022 — 09:00 Post Lock Read More Heavy analysis! Where did the core assets fall? Nearly half of the constituent stocks of the Mao Index fell by more than 50%, and many indexes retreated more than 2018. Some stocks have become the pioneers of rebound Post date May 16, 2022 — 08:55 Post Lock Read More [Opportunity Discovery] The Health and Health Commission requires companies related to the routine construction or renovation of a certain number of makeshift hospitals or has attracted attention Post date May 16, 2022 — 08:55 Post Lock Read More Zhongsheng Ruichuang's 3CL protease inhibitor clinical trial application was accepted by NMPA, and domestic new crown drugs accelerated Post date May 16, 2022 — 08:44 Post Lock Read More Ping An Securities: Give Xintian Pharmaceutical an Overweight Rating_Stock News_Market Gold Online Post date May 16, 2022 — 08:37 Post Lock Read More New crown oral drug clinical trial approved! Chinese medicine doubled the application of bull stocks after four days, and then made good profits, and institutions fled at high levels – yqqlm Post date May 15, 2022 — 23:27 Post Lock Read More *ST Kangmei appoints Liu Xinquan as the company's deputy general manager. The company's net profit in 2021 is 7.918 billion. Post date May 15, 2022 — 22:23 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Qianjin Pharmaceutical does not have Qianjin Tensudo to clarify the connection! Note that the inhibition data of 15,000 times the risk is only the result of in vitro experiments Post date May 16, 2022 — 23:09 Post Lock Read More Qianjin Pharmaceutical has no Qianjin phylloxacin, and many companies clarify the relationship! Pay attention to the risks, the inhibition data of 15,000 times are only the results of in vitro experiments. Post date May 16, 2022 — 23:07 Post Lock Read More Yunnan Baiyao: The company currently does not produce and sell fenugreek related products Post date May 16, 2022 — 23:00 Post Lock Read More It's not just you who have been cut leeks by the stock market! Yunnan Baiyao’s net profit fell 49% last year, and it lost nearly 2 billion by indulging in stocks Post date May 16, 2022 — 14:38 Post Lock Read More Zhendong Pharmaceutical: Filling the blank of Chinese medicine industry standards and realizing the rapid development of Chinese medicine industry Post date May 16, 2022 — 13:32 Post Lock Read More Zhendong Pharma helps the front line of Shanghai's anti-epidemic efforts and works together to keep "Shanghai" Post date May 16, 2022 — 13:14 Post Lock Read More Huaan Securities: Buy rating for Shouxiangu Post date May 16, 2022 — 10:12 Post Lock Read More [Opportunity Discovery] The Health and Health Commission requires the routine construction or renovation of a certain number of makeshift hospitals related companies or attracts attention_Oriental Fortune Net Post date May 16, 2022 — 09:00 Post Lock Read More Heavy analysis! Where did the core assets fall? Nearly half of the constituent stocks of the Mao Index fell by more than 50%, and many indexes retreated more than 2018. Some stocks have become the pioneers of rebound Post date May 16, 2022 — 08:55 Post Lock Read More [Opportunity Discovery] The Health and Health Commission requires companies related to the routine construction or renovation of a certain number of makeshift hospitals or has attracted attention Post date May 16, 2022 — 08:55 Post Lock Read More Zhongsheng Ruichuang's 3CL protease inhibitor clinical trial application was accepted by NMPA, and domestic new crown drugs accelerated Post date May 16, 2022 — 08:44 Post Lock Read More Ping An Securities: Give Xintian Pharmaceutical an Overweight Rating_Stock News_Market Gold Online Post date May 16, 2022 — 08:37 Post Lock Read More New crown oral drug clinical trial approved! Chinese medicine doubled the application of bull stocks after four days, and then made good profits, and institutions fled at high levels – yqqlm Post date May 15, 2022 — 23:27 Post Lock Read More *ST Kangmei appoints Liu Xinquan as the company's deputy general manager. The company's net profit in 2021 is 7.918 billion. Post date May 15, 2022 — 22:23 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Qianjin Pharmaceutical has no Qianjin phylloxacin, and many companies clarify the relationship! Pay attention to the risks, the inhibition data of 15,000 times are only the results of in vitro experiments. Post date May 16, 2022 — 23:07 Post Lock Read More Yunnan Baiyao: The company currently does not produce and sell fenugreek related products Post date May 16, 2022 — 23:00 Post Lock Read More It's not just you who have been cut leeks by the stock market! Yunnan Baiyao’s net profit fell 49% last year, and it lost nearly 2 billion by indulging in stocks Post date May 16, 2022 — 14:38 Post Lock Read More Zhendong Pharmaceutical: Filling the blank of Chinese medicine industry standards and realizing the rapid development of Chinese medicine industry Post date May 16, 2022 — 13:32 Post Lock Read More Zhendong Pharma helps the front line of Shanghai's anti-epidemic efforts and works together to keep "Shanghai" Post date May 16, 2022 — 13:14 Post Lock Read More Huaan Securities: Buy rating for Shouxiangu Post date May 16, 2022 — 10:12 Post Lock Read More [Opportunity Discovery] The Health and Health Commission requires the routine construction or renovation of a certain number of makeshift hospitals related companies or attracts attention_Oriental Fortune Net Post date May 16, 2022 — 09:00 Post Lock Read More Heavy analysis! Where did the core assets fall? Nearly half of the constituent stocks of the Mao Index fell by more than 50%, and many indexes retreated more than 2018. Some stocks have become the pioneers of rebound Post date May 16, 2022 — 08:55 Post Lock Read More [Opportunity Discovery] The Health and Health Commission requires companies related to the routine construction or renovation of a certain number of makeshift hospitals or has attracted attention Post date May 16, 2022 — 08:55 Post Lock Read More Zhongsheng Ruichuang's 3CL protease inhibitor clinical trial application was accepted by NMPA, and domestic new crown drugs accelerated Post date May 16, 2022 — 08:44 Post Lock Read More Ping An Securities: Give Xintian Pharmaceutical an Overweight Rating_Stock News_Market Gold Online Post date May 16, 2022 — 08:37 Post Lock Read More New crown oral drug clinical trial approved! Chinese medicine doubled the application of bull stocks after four days, and then made good profits, and institutions fled at high levels – yqqlm Post date May 15, 2022 — 23:27 Post Lock Read More *ST Kangmei appoints Liu Xinquan as the company's deputy general manager. The company's net profit in 2021 is 7.918 billion. Post date May 15, 2022 — 22:23 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Yunnan Baiyao: The company currently does not produce and sell fenugreek related products Post date May 16, 2022 — 23:00 Post Lock Read More It's not just you who have been cut leeks by the stock market! Yunnan Baiyao’s net profit fell 49% last year, and it lost nearly 2 billion by indulging in stocks Post date May 16, 2022 — 14:38 Post Lock Read More Zhendong Pharmaceutical: Filling the blank of Chinese medicine industry standards and realizing the rapid development of Chinese medicine industry Post date May 16, 2022 — 13:32 Post Lock Read More Zhendong Pharma helps the front line of Shanghai's anti-epidemic efforts and works together to keep "Shanghai" Post date May 16, 2022 — 13:14 Post Lock Read More Huaan Securities: Buy rating for Shouxiangu Post date May 16, 2022 — 10:12 Post Lock Read More [Opportunity Discovery] The Health and Health Commission requires the routine construction or renovation of a certain number of makeshift hospitals related companies or attracts attention_Oriental Fortune Net Post date May 16, 2022 — 09:00 Post Lock Read More Heavy analysis! Where did the core assets fall? Nearly half of the constituent stocks of the Mao Index fell by more than 50%, and many indexes retreated more than 2018. Some stocks have become the pioneers of rebound Post date May 16, 2022 — 08:55 Post Lock Read More [Opportunity Discovery] The Health and Health Commission requires companies related to the routine construction or renovation of a certain number of makeshift hospitals or has attracted attention Post date May 16, 2022 — 08:55 Post Lock Read More Zhongsheng Ruichuang's 3CL protease inhibitor clinical trial application was accepted by NMPA, and domestic new crown drugs accelerated Post date May 16, 2022 — 08:44 Post Lock Read More Ping An Securities: Give Xintian Pharmaceutical an Overweight Rating_Stock News_Market Gold Online Post date May 16, 2022 — 08:37 Post Lock Read More New crown oral drug clinical trial approved! Chinese medicine doubled the application of bull stocks after four days, and then made good profits, and institutions fled at high levels – yqqlm Post date May 15, 2022 — 23:27 Post Lock Read More *ST Kangmei appoints Liu Xinquan as the company's deputy general manager. The company's net profit in 2021 is 7.918 billion. Post date May 15, 2022 — 22:23 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
It's not just you who have been cut leeks by the stock market! Yunnan Baiyao’s net profit fell 49% last year, and it lost nearly 2 billion by indulging in stocks Post date May 16, 2022 — 14:38 Post Lock Read More Zhendong Pharmaceutical: Filling the blank of Chinese medicine industry standards and realizing the rapid development of Chinese medicine industry Post date May 16, 2022 — 13:32 Post Lock Read More Zhendong Pharma helps the front line of Shanghai's anti-epidemic efforts and works together to keep "Shanghai" Post date May 16, 2022 — 13:14 Post Lock Read More Huaan Securities: Buy rating for Shouxiangu Post date May 16, 2022 — 10:12 Post Lock Read More [Opportunity Discovery] The Health and Health Commission requires the routine construction or renovation of a certain number of makeshift hospitals related companies or attracts attention_Oriental Fortune Net Post date May 16, 2022 — 09:00 Post Lock Read More Heavy analysis! Where did the core assets fall? Nearly half of the constituent stocks of the Mao Index fell by more than 50%, and many indexes retreated more than 2018. Some stocks have become the pioneers of rebound Post date May 16, 2022 — 08:55 Post Lock Read More [Opportunity Discovery] The Health and Health Commission requires companies related to the routine construction or renovation of a certain number of makeshift hospitals or has attracted attention Post date May 16, 2022 — 08:55 Post Lock Read More Zhongsheng Ruichuang's 3CL protease inhibitor clinical trial application was accepted by NMPA, and domestic new crown drugs accelerated Post date May 16, 2022 — 08:44 Post Lock Read More Ping An Securities: Give Xintian Pharmaceutical an Overweight Rating_Stock News_Market Gold Online Post date May 16, 2022 — 08:37 Post Lock Read More New crown oral drug clinical trial approved! Chinese medicine doubled the application of bull stocks after four days, and then made good profits, and institutions fled at high levels – yqqlm Post date May 15, 2022 — 23:27 Post Lock Read More *ST Kangmei appoints Liu Xinquan as the company's deputy general manager. The company's net profit in 2021 is 7.918 billion. Post date May 15, 2022 — 22:23 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Zhendong Pharmaceutical: Filling the blank of Chinese medicine industry standards and realizing the rapid development of Chinese medicine industry Post date May 16, 2022 — 13:32 Post Lock Read More Zhendong Pharma helps the front line of Shanghai's anti-epidemic efforts and works together to keep "Shanghai" Post date May 16, 2022 — 13:14 Post Lock Read More Huaan Securities: Buy rating for Shouxiangu Post date May 16, 2022 — 10:12 Post Lock Read More [Opportunity Discovery] The Health and Health Commission requires the routine construction or renovation of a certain number of makeshift hospitals related companies or attracts attention_Oriental Fortune Net Post date May 16, 2022 — 09:00 Post Lock Read More Heavy analysis! Where did the core assets fall? Nearly half of the constituent stocks of the Mao Index fell by more than 50%, and many indexes retreated more than 2018. Some stocks have become the pioneers of rebound Post date May 16, 2022 — 08:55 Post Lock Read More [Opportunity Discovery] The Health and Health Commission requires companies related to the routine construction or renovation of a certain number of makeshift hospitals or has attracted attention Post date May 16, 2022 — 08:55 Post Lock Read More Zhongsheng Ruichuang's 3CL protease inhibitor clinical trial application was accepted by NMPA, and domestic new crown drugs accelerated Post date May 16, 2022 — 08:44 Post Lock Read More Ping An Securities: Give Xintian Pharmaceutical an Overweight Rating_Stock News_Market Gold Online Post date May 16, 2022 — 08:37 Post Lock Read More New crown oral drug clinical trial approved! Chinese medicine doubled the application of bull stocks after four days, and then made good profits, and institutions fled at high levels – yqqlm Post date May 15, 2022 — 23:27 Post Lock Read More *ST Kangmei appoints Liu Xinquan as the company's deputy general manager. The company's net profit in 2021 is 7.918 billion. Post date May 15, 2022 — 22:23 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Zhendong Pharma helps the front line of Shanghai's anti-epidemic efforts and works together to keep "Shanghai" Post date May 16, 2022 — 13:14 Post Lock Read More Huaan Securities: Buy rating for Shouxiangu Post date May 16, 2022 — 10:12 Post Lock Read More [Opportunity Discovery] The Health and Health Commission requires the routine construction or renovation of a certain number of makeshift hospitals related companies or attracts attention_Oriental Fortune Net Post date May 16, 2022 — 09:00 Post Lock Read More Heavy analysis! Where did the core assets fall? Nearly half of the constituent stocks of the Mao Index fell by more than 50%, and many indexes retreated more than 2018. Some stocks have become the pioneers of rebound Post date May 16, 2022 — 08:55 Post Lock Read More [Opportunity Discovery] The Health and Health Commission requires companies related to the routine construction or renovation of a certain number of makeshift hospitals or has attracted attention Post date May 16, 2022 — 08:55 Post Lock Read More Zhongsheng Ruichuang's 3CL protease inhibitor clinical trial application was accepted by NMPA, and domestic new crown drugs accelerated Post date May 16, 2022 — 08:44 Post Lock Read More Ping An Securities: Give Xintian Pharmaceutical an Overweight Rating_Stock News_Market Gold Online Post date May 16, 2022 — 08:37 Post Lock Read More New crown oral drug clinical trial approved! Chinese medicine doubled the application of bull stocks after four days, and then made good profits, and institutions fled at high levels – yqqlm Post date May 15, 2022 — 23:27 Post Lock Read More *ST Kangmei appoints Liu Xinquan as the company's deputy general manager. The company's net profit in 2021 is 7.918 billion. Post date May 15, 2022 — 22:23 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Huaan Securities: Buy rating for Shouxiangu Post date May 16, 2022 — 10:12 Post Lock Read More [Opportunity Discovery] The Health and Health Commission requires the routine construction or renovation of a certain number of makeshift hospitals related companies or attracts attention_Oriental Fortune Net Post date May 16, 2022 — 09:00 Post Lock Read More Heavy analysis! Where did the core assets fall? Nearly half of the constituent stocks of the Mao Index fell by more than 50%, and many indexes retreated more than 2018. Some stocks have become the pioneers of rebound Post date May 16, 2022 — 08:55 Post Lock Read More [Opportunity Discovery] The Health and Health Commission requires companies related to the routine construction or renovation of a certain number of makeshift hospitals or has attracted attention Post date May 16, 2022 — 08:55 Post Lock Read More Zhongsheng Ruichuang's 3CL protease inhibitor clinical trial application was accepted by NMPA, and domestic new crown drugs accelerated Post date May 16, 2022 — 08:44 Post Lock Read More Ping An Securities: Give Xintian Pharmaceutical an Overweight Rating_Stock News_Market Gold Online Post date May 16, 2022 — 08:37 Post Lock Read More New crown oral drug clinical trial approved! Chinese medicine doubled the application of bull stocks after four days, and then made good profits, and institutions fled at high levels – yqqlm Post date May 15, 2022 — 23:27 Post Lock Read More *ST Kangmei appoints Liu Xinquan as the company's deputy general manager. The company's net profit in 2021 is 7.918 billion. Post date May 15, 2022 — 22:23 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
[Opportunity Discovery] The Health and Health Commission requires the routine construction or renovation of a certain number of makeshift hospitals related companies or attracts attention_Oriental Fortune Net Post date May 16, 2022 — 09:00 Post Lock Read More Heavy analysis! Where did the core assets fall? Nearly half of the constituent stocks of the Mao Index fell by more than 50%, and many indexes retreated more than 2018. Some stocks have become the pioneers of rebound Post date May 16, 2022 — 08:55 Post Lock Read More [Opportunity Discovery] The Health and Health Commission requires companies related to the routine construction or renovation of a certain number of makeshift hospitals or has attracted attention Post date May 16, 2022 — 08:55 Post Lock Read More Zhongsheng Ruichuang's 3CL protease inhibitor clinical trial application was accepted by NMPA, and domestic new crown drugs accelerated Post date May 16, 2022 — 08:44 Post Lock Read More Ping An Securities: Give Xintian Pharmaceutical an Overweight Rating_Stock News_Market Gold Online Post date May 16, 2022 — 08:37 Post Lock Read More New crown oral drug clinical trial approved! Chinese medicine doubled the application of bull stocks after four days, and then made good profits, and institutions fled at high levels – yqqlm Post date May 15, 2022 — 23:27 Post Lock Read More *ST Kangmei appoints Liu Xinquan as the company's deputy general manager. The company's net profit in 2021 is 7.918 billion. Post date May 15, 2022 — 22:23 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Heavy analysis! Where did the core assets fall? Nearly half of the constituent stocks of the Mao Index fell by more than 50%, and many indexes retreated more than 2018. Some stocks have become the pioneers of rebound Post date May 16, 2022 — 08:55 Post Lock Read More [Opportunity Discovery] The Health and Health Commission requires companies related to the routine construction or renovation of a certain number of makeshift hospitals or has attracted attention Post date May 16, 2022 — 08:55 Post Lock Read More Zhongsheng Ruichuang's 3CL protease inhibitor clinical trial application was accepted by NMPA, and domestic new crown drugs accelerated Post date May 16, 2022 — 08:44 Post Lock Read More Ping An Securities: Give Xintian Pharmaceutical an Overweight Rating_Stock News_Market Gold Online Post date May 16, 2022 — 08:37 Post Lock Read More New crown oral drug clinical trial approved! Chinese medicine doubled the application of bull stocks after four days, and then made good profits, and institutions fled at high levels – yqqlm Post date May 15, 2022 — 23:27 Post Lock Read More *ST Kangmei appoints Liu Xinquan as the company's deputy general manager. The company's net profit in 2021 is 7.918 billion. Post date May 15, 2022 — 22:23 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
[Opportunity Discovery] The Health and Health Commission requires companies related to the routine construction or renovation of a certain number of makeshift hospitals or has attracted attention Post date May 16, 2022 — 08:55 Post Lock Read More Zhongsheng Ruichuang's 3CL protease inhibitor clinical trial application was accepted by NMPA, and domestic new crown drugs accelerated Post date May 16, 2022 — 08:44 Post Lock Read More Ping An Securities: Give Xintian Pharmaceutical an Overweight Rating_Stock News_Market Gold Online Post date May 16, 2022 — 08:37 Post Lock Read More New crown oral drug clinical trial approved! Chinese medicine doubled the application of bull stocks after four days, and then made good profits, and institutions fled at high levels – yqqlm Post date May 15, 2022 — 23:27 Post Lock Read More *ST Kangmei appoints Liu Xinquan as the company's deputy general manager. The company's net profit in 2021 is 7.918 billion. Post date May 15, 2022 — 22:23 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Zhongsheng Ruichuang's 3CL protease inhibitor clinical trial application was accepted by NMPA, and domestic new crown drugs accelerated Post date May 16, 2022 — 08:44 Post Lock Read More Ping An Securities: Give Xintian Pharmaceutical an Overweight Rating_Stock News_Market Gold Online Post date May 16, 2022 — 08:37 Post Lock Read More New crown oral drug clinical trial approved! Chinese medicine doubled the application of bull stocks after four days, and then made good profits, and institutions fled at high levels – yqqlm Post date May 15, 2022 — 23:27 Post Lock Read More *ST Kangmei appoints Liu Xinquan as the company's deputy general manager. The company's net profit in 2021 is 7.918 billion. Post date May 15, 2022 — 22:23 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Ping An Securities: Give Xintian Pharmaceutical an Overweight Rating_Stock News_Market Gold Online Post date May 16, 2022 — 08:37 Post Lock Read More New crown oral drug clinical trial approved! Chinese medicine doubled the application of bull stocks after four days, and then made good profits, and institutions fled at high levels – yqqlm Post date May 15, 2022 — 23:27 Post Lock Read More *ST Kangmei appoints Liu Xinquan as the company's deputy general manager. The company's net profit in 2021 is 7.918 billion. Post date May 15, 2022 — 22:23 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
New crown oral drug clinical trial approved! Chinese medicine doubled the application of bull stocks after four days, and then made good profits, and institutions fled at high levels – yqqlm Post date May 15, 2022 — 23:27 Post Lock Read More *ST Kangmei appoints Liu Xinquan as the company's deputy general manager. The company's net profit in 2021 is 7.918 billion. Post date May 15, 2022 — 22:23 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
*ST Kangmei appoints Liu Xinquan as the company's deputy general manager. The company's net profit in 2021 is 7.918 billion. Post date May 15, 2022 — 22:23 Post Lock Read More
Caishen.CoCaishen.Co